KBC Group’s Apogee Therapeutics APGE Stock Holding History

KBC Group’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.11M	Buy	38,496 +653	+2%	+$58.8K	0.01%	497
2026 Q1	$3.19M	Buy	+37,843	New	+$2.75M	0.01%	567

Other funds holding APGE

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

KBC Group's APGE Position: Q2 2026 in Review

KBC Group increased its Apogee Therapeutics (APGE) stake by 1.7% in Q2 2026, buying an estimated $58.8K and bringing the position to 38,496 shares worth $5.11M. The position accounts for 0.01% of the portfolio, ranked #497.

KBC Group first reported a position in APGE in Q1 2026 and has held it in 2 quarters since. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

KBC Group held 38,496 shares of Apogee Therapeutics worth $5.11M as of Q2 2026.
KBC Group bought 653 Apogee Therapeutics shares in Q2 2026, an estimated $58.8K.
Apogee Therapeutics made up 0.01% of KBC Group's portfolio in Q2 2026, its #497 holding.
KBC Group first reported a position in Apogee Therapeutics in Q1 2026 and has held it in 2 quarters since.
289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.